コンテンツへスキップ
Merck

Lactulose and renal failure.

Scandinavian journal of gastroenterology. Supplement (1997-01-01)
B Vogt, F J Frey
要旨

The introduction of lactulose as a new therapeutic agent for treatment of hepatic encephalopathy was a major breakthrough in this field. It was hypothesized that lactulose might prevent postoperative renal impairment after biliary surgery in patients with obstructive jaundice. The presumable mechanism purported was the diminished endotoxinemia by lactulose. Unfortunately, such a reno-protective effect has not been shown conclusively until now in clinical studies. In chronic renal failure lactulose is known to promote fecal excretion of water, sodium, potassium, amonium, urea, creatinine and protons. Thus, lactulose could be useful for the treatment of chronic renal failure. However, compliance to the therapy represents a major problem.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ラクツロース, ≥98.0% (HPLC)
Sigma-Aldrich
ラクツロース, ≥95% (HPLC)
USP
ラクツロース, United States Pharmacopeia (USP) Reference Standard
ラクツロース, European Pharmacopoeia (EP) Reference Standard
ラクツロース, European Pharmacopoeia (EP) Reference Standard